Giving patients with a common form of breast cancer an immunotherapy drug before surgery appears to boost outcomes, a n ...

在乳腺癌的研究领域，来自意大利圣心天主教大学（Università Cattolica del Sacro Cuore）医学肿瘤学系等多个单位的研究人员取得了重要进展。第一作者 Luca Mastrantoni 所在的研究团队在 npj Breast Cancer 期刊上发表了题为 “Accessible model predicts response in hormone receptor po ...

The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...

For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 ...

A phase 3 clinical trial has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved – almost ...

After a second breast cancer diagnosis at 61, I faced 17 rounds of chemo, surgery and radiation, changing my perspective on life and leading to a new normal.

The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

Patients diagnosed with more advanced breast cancer are more likely to have cardiovascular disease, a large study suggests.

During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast ...

The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...

The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...